NO791643L - Cancer-tilknyttet protein og fremgangsmaate for fremstilling derav - Google Patents
Cancer-tilknyttet protein og fremgangsmaate for fremstilling deravInfo
- Publication number
- NO791643L NO791643L NO791643A NO791643A NO791643L NO 791643 L NO791643 L NO 791643L NO 791643 A NO791643 A NO 791643A NO 791643 A NO791643 A NO 791643A NO 791643 L NO791643 L NO 791643L
- Authority
- NO
- Norway
- Prior art keywords
- iac
- cadet
- antibodies
- protein
- antibody
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 45
- 102000004169 proteins and genes Human genes 0.000 title claims description 44
- 206010028980 Neoplasm Diseases 0.000 title claims description 32
- 201000011510 cancer Diseases 0.000 title claims description 32
- 238000000034 method Methods 0.000 title claims description 30
- 239000000463 material Substances 0.000 claims description 20
- 230000003053 immunization Effects 0.000 claims description 17
- 238000001042 affinity chromatography Methods 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 14
- 102000018358 immunoglobulin Human genes 0.000 claims description 14
- 229940072221 immunoglobulins Drugs 0.000 claims description 13
- 229920004890 Triton X-100 Polymers 0.000 claims description 12
- 239000013504 Triton X-100 Substances 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 12
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 12
- 238000010828 elution Methods 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000003599 detergent Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000002826 placenta Anatomy 0.000 claims description 9
- 239000011544 gradient gel Substances 0.000 claims description 7
- 230000000937 inactivator Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 230000003169 placental effect Effects 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 2
- 238000005377 adsorption chromatography Methods 0.000 claims 1
- 238000001641 gel filtration chromatography Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000002523 gelfiltration Methods 0.000 description 13
- 241000282887 Suidae Species 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 230000000890 antigenic effect Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000012506 Sephacryl® Substances 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002796 poly[α-(4-aminobutyl)-L-glycolic acid) Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK216378 | 1978-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO791643L true NO791643L (no) | 1979-11-20 |
Family
ID=8110498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO791643A NO791643L (no) | 1978-05-17 | 1979-05-16 | Cancer-tilknyttet protein og fremgangsmaate for fremstilling derav |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPS5516291A (fr) |
| AU (1) | AU521404B2 (fr) |
| BE (1) | BE876301A (fr) |
| DE (1) | DE2919833A1 (fr) |
| ES (1) | ES480624A1 (fr) |
| FI (1) | FI791551A (fr) |
| FR (1) | FR2426055A1 (fr) |
| GB (1) | GB2021593A (fr) |
| IT (1) | IT7968046A0 (fr) |
| LU (1) | LU81273A1 (fr) |
| NL (1) | NL7903854A (fr) |
| NO (1) | NO791643L (fr) |
| NZ (1) | NZ190470A (fr) |
| PT (1) | PT69617A (fr) |
| SE (1) | SE7904276L (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO830570L (no) * | 1982-02-22 | 1983-08-23 | Carlton Med Prod | Antistoffer og antigener for diagnose og behandling av cancer |
| AU569467B2 (en) * | 1982-04-07 | 1988-02-04 | Baylor College Of Medicine | Immunoglobulin based cancer treating pharmaceutical compositions |
-
1979
- 1979-05-15 SE SE7904276A patent/SE7904276L/ not_active Application Discontinuation
- 1979-05-15 FI FI791551A patent/FI791551A/fi not_active Application Discontinuation
- 1979-05-16 BE BE6/46832A patent/BE876301A/fr unknown
- 1979-05-16 PT PT69617A patent/PT69617A/fr unknown
- 1979-05-16 ES ES480624A patent/ES480624A1/es not_active Expired
- 1979-05-16 NZ NZ190470A patent/NZ190470A/xx unknown
- 1979-05-16 FR FR7912426A patent/FR2426055A1/fr not_active Withdrawn
- 1979-05-16 NL NL7903854A patent/NL7903854A/xx not_active Application Discontinuation
- 1979-05-16 LU LU81273A patent/LU81273A1/fr unknown
- 1979-05-16 DE DE19792919833 patent/DE2919833A1/de not_active Withdrawn
- 1979-05-16 NO NO791643A patent/NO791643L/no unknown
- 1979-05-16 GB GB7917107A patent/GB2021593A/en not_active Withdrawn
- 1979-05-17 AU AU47172/79A patent/AU521404B2/en not_active Ceased
- 1979-05-17 JP JP6213379A patent/JPS5516291A/ja active Pending
- 1979-05-17 IT IT7968046A patent/IT7968046A0/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES480624A1 (es) | 1980-08-16 |
| FR2426055A1 (fr) | 1979-12-14 |
| AU4717279A (en) | 1979-11-22 |
| BE876301A (fr) | 1979-11-16 |
| AU521404B2 (en) | 1982-04-01 |
| NZ190470A (en) | 1982-06-29 |
| LU81273A1 (fr) | 1979-09-10 |
| PT69617A (fr) | 1979-06-01 |
| NL7903854A (nl) | 1979-11-20 |
| JPS5516291A (en) | 1980-02-04 |
| GB2021593A (en) | 1979-12-05 |
| FI791551A (fi) | 1979-11-18 |
| DE2919833A1 (de) | 1979-11-29 |
| SE7904276L (sv) | 1979-11-18 |
| IT7968046A0 (it) | 1979-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Muller-Eberhard et al. | Isolation and description of the fourth component of human complement | |
| Ballow et al. | Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them | |
| Dahl et al. | Glial fibrillary acidic protein from normal human brain. Purification and properties | |
| Clark et al. | Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus | |
| US3995018A (en) | Method of binding immunoglobulin employing a polypeptide from microorganisms | |
| Kennel et al. | Isolation and characterization of plasma membrane associated immunoglobulin from cultured human diploid lymphocytes | |
| Reisfeld et al. | Association of HL-A antigens and β 2-microglobulin at the cellular and molecular level | |
| Mannik et al. | Antibody-agarose immunoadsorbents: complete removal of classes of immunoglobulins from serum | |
| DK150810B (da) | Fremgangsmaade til bestemmelse af et eller flere antigener i en proeve ved hjaelp af antistof bundet til smaa partikler | |
| CA1265048A (fr) | Proteine caracteristique de l'arthtrite rheumatoide | |
| Dunne et al. | Schistosoma mansoni egg antigens: preparation of rabbit antisera with monospecific immunoprecipitating activity, and their use in antigen characterization | |
| Olson et al. | Localization of phosphoprotein C23 in nucleoli by immunological methods | |
| Quinn et al. | Early pregnancy factor in liver regeneration after partial hepatectomy in rats: relationship with chaperonin 10 | |
| Kriegler et al. | Phenotypic complementation of the SV40 tsA mutant defect in viral DNA synthesis following microinjection of SV40 T antigen | |
| CA1101847A (fr) | Traduction non-disponible | |
| US5030578A (en) | Process for the purification of C1-inhibitor | |
| NO791643L (no) | Cancer-tilknyttet protein og fremgangsmaate for fremstilling derav | |
| Nielsen et al. | Cell-cell adhesion in the embryonic chick: partial purification of liver adhesion molecules from liver membranes | |
| Aasted | Purification and characterization of Aleutian disease virus | |
| WO2019128758A1 (fr) | Anticorps destiné à être utilisé dans la détection d'un dommage de stade précoce de la barrière hémato-encéphalique pendant un accident ischémique cérébral et application associée | |
| Gordon et al. | An improved method of preparing haptoglobin polypeptide chains using guanidine hydrochloride | |
| Lahav et al. | Biological activity of the cleavage product of human immunoglobulin G with cyanogen bromide | |
| Hughes et al. | The immunopurification of tetanus toxoid | |
| CA1086306A (fr) | Reactif pour epreuve d'immunofluorescence et procede de preparation | |
| Leroy | Precipitating and complement-fixing antibodies to collagen with species and collagen subunit specificity |